RxDoctor Payments Data

Syed Farhan Zaidi, MD

Physical Medicine & Rehabilitation · Palm Bay, FLNPI 1215940564

Payments from drug & device makers

$1,831in general payments, 2019–2025

Across 78 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$289
  • Pfizer$258
  • Medtronic$203
  • Johnson & Johnson$179
  • Stimwave Technologies Incorporated$113
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$111
  • plus $678 from 15 others

What the payments were for

  • Food & beverage$1,80198%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,831 in reported general payments places this provider in the 80th percentile of 618 physical medicine & rehabilitation providers in Florida.

See all physical medicine & rehabilitation providers in Florida

Medicare billing

Part B allowed, 2024
$529,333
Medicare patients
569
Services billed
7,001

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate62$39,715
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen906$37,832
OxycontinOxycodone Hcl53$30,539
Oxycodone Hcl1,000$19,901
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen594$18,554
MovantikNaloxegol Oxalate31$13,869
Morphine Sulfate ErMorphine Sulfate337$8,507
Naloxone Hcl117$7,459
Gabapentin297$5,187
Fentanyl47$4,978
Pregabalin159$4,959
Hydromorphone ErHydromorphone Hcl14$4,779
Methocarbamol195$3,584
Tizanidine Hcl162$2,868
Morphine Sulfate121$2,693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$18$39,71562 claims
Redhill Biopharma Inc.Movantik$18$13,86931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 618 physical medicine & rehabilitation providers in Florida.

Other physical medicine & rehabilitation in Palm Bay

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →